Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Color additives

This article was originally published in The Rose Sheet

Executive Summary

Nail polish manufacturer FEM, Inc. (Santa Barbara, Calif.) petitions FDA to amend color additive regulation to eliminate the limitation on the amount of silver used in nail polish, the agency announces in a Federal Register notice Aug. 18. FDA currently limits the use of silver to 1% of the finished product. Silver, certified in 1997, is one of 29 color additives exempt from batch certification; FDA most recently approved zinc sulfide in a Federal Register notice Aug. 8 (1"The Rose Sheet" Aug. 14, p. 10)

You may also be interested in...



Zinc Sulfide Color Additive Approval Restricted To "Infrequent Use" - FDA

FDA's approval of color additive luminescent zinc sulfide without batch certification is the first such authorization by the agency in almost 20 years. Zinc sulfide's approval for use in certain cosmetics was announced in a Federal Register notice Aug. 8.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Latest Headlines
See All
UsernamePublicRestriction

Register

RS008325

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel